You are here

  • Home
  • Archive
  • Volume 9, Issue 8
  • HPV-16 E6/E7 DNA tattoo vaccination using genetically optimized vaccines elicit clinical and immunological responses in patients with usual vulvar intraepithelial neoplasia (uVIN): a phase I/II clinical trial

Article info

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
HPV-16 E6/E7 DNA tattoo vaccination using genetically optimized vaccines elicit clinical and immunological responses in patients with usual vulvar intraepithelial neoplasia (uVIN): a phase I/II clinical trial

Authors

  • Noor Alida Maria Bakker Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute – Antoni van Leeuwenhoek, Amsterdam, The NetherlandsDivision of Tumor Biology and Immunology, The Netherlands Cancer Institute – Antoni van Leeuwenhoek, Amsterdam, The NetherlandsOncode Institute, Utrecht, The Netherlands PubMed articlesGoogle scholar articles
  • Jossie Rotman Center for Gynecologic Oncology Amsterdam (CGOA), The Netherlands Cancer Institute – Antoni van Leeuwenhoek, Amsterdam, The NetherlandsCenter for Gynecological Oncology Amsterdam (CGOA), Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands PubMed articlesGoogle scholar articles
  • Marc van Beurden Center for Gynecologic Oncology Amsterdam (CGOA), The Netherlands Cancer Institute – Antoni van Leeuwenhoek, Amsterdam, The Netherlands PubMed articlesGoogle scholar articles
  • Henry J MAA Zijlmans Center for Gynecologic Oncology Amsterdam (CGOA), The Netherlands Cancer Institute – Antoni van Leeuwenhoek, Amsterdam, The Netherlands PubMed articlesGoogle scholar articles
  • Maartje van Ruiten Center for Gynecologic Oncology Amsterdam (CGOA), The Netherlands Cancer Institute – Antoni van Leeuwenhoek, Amsterdam, The Netherlands PubMed articlesGoogle scholar articles
  • Sanne Samuels Center for Gynecologic Oncology Amsterdam (CGOA), The Netherlands Cancer Institute – Antoni van Leeuwenhoek, Amsterdam, The NetherlandsCenter for Gynecological Oncology Amsterdam (CGOA), Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands PubMed articlesGoogle scholar articles
  • Bastiaan Nuijen Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute – Antoni van Leeuwenhoek, Amsterdam, The Netherlands PubMed articlesGoogle scholar articles
  • Jos Beijnen Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute – Antoni van Leeuwenhoek, Amsterdam, The Netherlands PubMed articlesGoogle scholar articles
  • Karin De Visser Division of Tumor Biology and Immunology, The Netherlands Cancer Institute – Antoni van Leeuwenhoek, Amsterdam, The NetherlandsOncode Institute, Utrecht, The Netherlands PubMed articlesGoogle scholar articles
  • John Haanen Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute – Antoni van Leeuwenhoek, Amsterdam, The NetherlandsDepartment of Medical Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands PubMed articlesGoogle scholar articles
  • Ton Schumacher Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute – Antoni van Leeuwenhoek, Amsterdam, The NetherlandsOncode Institute, Utrecht, The Netherlands PubMed articlesGoogle scholar articles
  • Tanja D de Gruijl Department of Medical Oncology, —Cancer Center Amsterdam, Amsterdam UMC—Vrije Universiteit, Amsterdam, The Netherlands PubMed articlesGoogle scholar articles
  • Ekaterina S Jordanova Center for Gynecological Oncology Amsterdam (CGOA), Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands PubMed articlesGoogle scholar articles
  • Gemma G Kenter Center for Gynecologic Oncology Amsterdam (CGOA), The Netherlands Cancer Institute – Antoni van Leeuwenhoek, Amsterdam, The NetherlandsCenter for Gynecological Oncology Amsterdam (CGOA), Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands PubMed articlesGoogle scholar articles
  • Joost H van den Berg Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute – Antoni van Leeuwenhoek, Amsterdam, The NetherlandsDepartment of Pharmacy and Pharmacology, The Netherlands Cancer Institute – Antoni van Leeuwenhoek, Amsterdam, The Netherlands PubMed articlesGoogle scholar articles
  • Nienke E van Trommel Center for Gynecologic Oncology Amsterdam (CGOA), The Netherlands Cancer Institute – Antoni van Leeuwenhoek, Amsterdam, The Netherlands PubMed articlesGoogle scholar articles

Citation

Bakker NAM, Rotman J, van Beurden M, et al
HPV-16 E6/E7 DNA tattoo vaccination using genetically optimized vaccines elicit clinical and immunological responses in patients with usual vulvar intraepithelial neoplasia (uVIN): a phase I/II clinical trial
Journal for ImmunoTherapy of Cancer 2021;9:e002547. doi: 10.1136/jitc-2021-002547
Online issue publication 
November 02, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.